Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.36 |
| ▸ | PARP1 | P09874 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.32 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510164 | 0.73 | CYP1A2 (0.39) | PARP10PARP1KDM4EHTR1ASLC6A4 | |
| SCHEMBL4490589 | 0.73 | MAPT (0.33) | PARP10PARP1KDM4EHTR1ASLC6A4 | |
| SCHEMBL31354789 | 0.70 | PARP10 (0.46) | PARP10PARP1KDM4EGRM5PARP11 | |
| SCHEMBL4492639 | 0.68 | HTR1A (0.49) | PARP10PARP1KDM4EHTR1ASLC6A4 | |
| SCHEMBL609771 | 0.66 | PARP10 (0.50) | PARP10PARP1KDM4EGRM5PARP11 | |
| SCHEMBL4494952 | 0.64 | HTR1A (0.46) | PARP10PARP1KDM4EHTR1ASLC6A4 | |
| SCHEMBL22713717 | 0.64 | PARP10 (0.44) | PARP10PARP1KDM4EGRM5PARP11 | |
| SCHEMBL1725137 | 0.64 | PARP10 (0.51) | PARP10PARP1KDM4EGRM5PARP11 | |
| SCHEMBL15814960 | 0.64 | PARP10 (0.41) | PARP10PARP1KDM4EGRM5PARP11 | |
| SCHEMBL15466514 | 0.62 | PARP10 (0.62) | PARP10PARP1KDM4EGRM5PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495111-B2 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1893617-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | PARP10 2908/4885PARP1 3440/4885KDM4E 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.